3β-Amino-22,26-epimino-16β,23-epoxy-5α,22αH-25βH-cholestanol-(23β) | 23031-68-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β-Amino-22,26-epimino-16β,23-epoxy-5α,22αH-25βH-cholestanol-(23β)
• 英文别名: Solanocapsin；3β-Amino-22,26-imino-16β,23-oxido-5α,22α,23β,25α-cholestan-23-ol, Solanocapsin；Naphth[2'',1'':4',5']indeno[1',2':5,6]pyrano[3,2-b]pyridin-11a(1H)-ol,2-aminodocosahydro-4a,6a,7,10-tetramethyl-,(2S,4aS,4bS,6aS,6bR,7S,7aR,10R,11aS,12aR,13aS,13bR,15aS)-；(1S,2R,5S,7S,10S,11S,14S,15R,16S,17R,20R,22S,24S)-7-amino-10,14,16,20-tetramethyl-23-oxa-18-azahexacyclo[12.11.0.02,11.05,10.015,24.017,22]pentacosan-22-ol
• CAS: 23031-68-7
• 化学式: C₂₇H₄₆N₂O₂
• 分子量: 430.674
• InChiKey: ZPTJKUUQUDRHTL-AEEMEBLISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  67.5
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• DIHYDROARTEMISININ-STEROID CONJUGATE AND PREPARATION METHOD AND USE THEREOF
  申请人：Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd.

  公开号：EP3617218A1

  公开（公告）日：2020-03-04

  Described is a dihydroartemisinin-steroid conjugate of formula (I), or a pharmaceutically acceptable salt thereof, where position 10 of dihydroartemisinin is linked to the steroid through a linker X. This application further provides a preparation method of the dihydroartemisinin-steroid conjugate and an application of the dihydroartemisinin-steroid conjugate in the preparation of a drug for treating cancer. The dihydroartemisinin-steroid conjugate of the invention exhibits potent inhibitory activity against various tumor cells and low cytotoxicity, moreover, the conjugate is capable of penetrating the blood-brain barrier, having a broad application prospect.

  本申请进一步提供了双氢青蒿素-类固醇共轭物的制备方法以及双氢青蒿素-类固醇共轭物在制备治疗癌症药物中的应用。本发明的双氢青蒿素-类固醇共轭物对多种肿瘤细胞具有强效抑制活性，细胞毒性低，而且共轭物能够穿透血脑屏障，具有广阔的应用前景。
• Dihydroartemisinin-steroid conjugate and preparation method and application thereof
  申请人：YUNBAIYAO ZHENGWU SCIENCE AND TECHNOLOGY (SHANGHAI) CO., LTD.

  公开号：US10881636B2

  公开（公告）日：2021-01-05

  Described is a dihydroartemisinin-steroid conjugate of formula (I), or a pharmaceutically acceptable salt thereof, where position 10 of dihydroartemisinin is linked to the steroid through a linker X. This application further provides a preparation method of the dihydroartemisinin-steroid conjugate and an application of the dihydroartemisinin-steroid conjugate in the preparation of a drug for treating cancer. The dihydroartemisinin-steroid conjugate of the invention exhibits potent inhibitory activity against various tumor cells and low cytotoxicity, moreover, the conjugate is capable of penetrating the blood-brain barrier, having a broad application prospect.

  本申请进一步提供了双氢青蒿素-类固醇共轭物的制备方法以及双氢青蒿素-类固醇共轭物在制备治疗癌症药物中的应用。 本发明的双氢青蒿素-类固醇共轭物对多种肿瘤细胞具有强效抑制活性，细胞毒性低，而且共轭物能够穿透血脑屏障，具有广阔的应用前景。
• Use of steroidal alkaloids to reverse multidrug resistance
  申请人：——

  公开号：US20030114393A1

  公开（公告）日：2003-06-19

  The invention provides steroidal alkaloids for inhibiting or reversing multidrug resistance in cancer or in bacterial, fungal or parasitic infections. The steroidal alkaloid may be administered to the patient alone or in combination with an anticancer, antibacterial, antifungal or antiparasitic agent. Examples of steroidal alkaloids include members of the solanidane or spirosolane e.g. tomatidine, families, and C-nor-D-homo steroid such as of the jervane or veratramine families.

  本发明提供的甾体生物碱可抑制或逆转癌症或细菌、真菌或寄生虫感染的多药耐药性。甾体生物碱可单独或与抗癌剂、抗菌剂、抗真菌剂或抗寄生虫剂联合施用。类固醇生物碱的例子包括茄尼烷或螺环烷（如番茄碱）家族成员，以及C-去甲-D-高类固醇（如泽凡或维拉曲明家族成员）。
• Glycoalkaloid compositions and various uses thereof
  申请人：SOLBEC PHARMACEUTICALS LIMITED

  公开号：US20040053857A1

  公开（公告）日：2004-03-18

  A composition comprising at least two glycoalkaloids of formula I: 1 wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V): 2 each of R 1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR 4 ; each of R 2 is a radical separately selected from the group consisting of hydrogen, amino and OR 4 ; each of R 3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; “X” is a radical selected from the group comprising —CH 2 —, —O— and —NH 2 —; and wherein the compound includes at least one R 4 group that is a carbohydrate or a derivative thereof selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH 2 OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; wherein the ratio of said glycoalkaloids is between 6:1 and 1:6 and on the proviso that when the glycoalkaloids are solamargine and solasonine and they are present in a 1:1 ratio the solamargine and solasonine are isolated.

  一种包含至少两种式 I 的糖类生物碱的组合物： 1 其中：虚线中的一条或两条代表双键，另一条代表单键，或两条都代表单键； A：代表选自下列通式（II）至（V）的基团： 2 每个 R 1 分别是从氢、氨基、氧代和 OR 组成的组中选出的基团 4 ; 每个 R 2 是分别选自氢、氨基和 OR 4 ; 每个 R 3 是分别选自由氢、碳水化合物和碳水化合物衍生物组成的基团； "X" 是一个基团，选自由 -CH 2 -、-O- 和-NH 2 -；以及 其中化合物包括至少一个 R 4 基团为碳水化合物或其衍生物，该碳水化合物或其衍生物选自以下组：甘油醛、甘油糖、赤藓糖、苏糖、核糖、阿拉伯糖、木糖、莱克糖、阿拓糖、阿洛糖、古洛糖、甘露糖、葡萄糖、饴糖、半乳糖、塔尔糖、鼠李糖、二羟基内酯、赤藓糖醇、核酮糖、木糖、棉子糖、果糖、山梨糖、塔格糖，以及其他六糖、庚糖、辛糖、纳糖、癸糖、带支链的脱氧糖（如apiose、hamamelose）。如apiose、hamamelose、streptose、cordycepose、mycarose 和 cladinose），醛基、酮基或羟基被取代的化合物（如 N-乙酰基、乙酰基、甲基、取代 CH 2 OH）、糖醇、糖酸、苯并咪唑、碳水化合物的烯醇盐、糖精酸、糖磷酸盐； 其中所述糖类生物碱的比例介于 6:1 和 1:6 之间，但条件是当糖类生物碱为索拉马辛和索拉索辛，且它们以 1:1 的比例存在时，索拉马辛和索拉索辛被分离出来。
• Methods of modulating IL-6
  申请人：Carter John Stephen

  公开号：US20050090453A1

  公开（公告）日：2005-04-28

  Use of a glycoalkaloid composition containing at least one Z Glycoalkaloid of formula 1: wherein: either one or both of the dotted lines represents a double bond, and the other a single bond, or both represent single bonds; A: represents a radical selected from the following radicals of general formulae (II) to (V): each of R 1 is a radical separately selected from the group consisting of hydrogen, amino, oxo and OR 4 ; each of R 2 is a radical separately selected from the group consisting of hydrogen, amino and OR 4 ; each of R 3 is a radical separately selected from the group consisting of hydrogen, carbohydrate and a carbohydrate derivative; “X” is a radical selected from the group comprising —CH 2 —, —O— and —NH 2 —; and wherein the compound includes at least one R 4 group that is a carbohydrate or a derivative such as one selected from the group comprising glyceric aldehyde, glycerose, erythrose, threose, ribose, arabinose, xylose, lyxose, altrose, allose, gulose, mannose, glucose, idose, galactose, talose, rhamnose, dihydroxyactone, erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose, and other hexoses, heptoses, octoses, nanoses, decoses, deoxysugars with branched chains, (e.g. apiose, hamamelose, streptose, cordycepose, mycarose and cladinose), compounds wherein the aldehyde, ketone or hydroxyl groups have been substituted (e.g. N-acetyl, acetyl, methyl, replacement of CH 2 OH), sugar alcohols, sugar acids, benzimidazoles, the enol salts of the carbohydrates, saccharinic acids, sugar phosphates; as an IL-6 antagonist.

  含有至少一种式 1 的 Z 甘氨醛组合物的用途： 其中：虚线中的一条或两条代表双键，另一条代表单键，或两条都代表单键； A：代表选自下列通式（II）至（V）的基团： R 1 分别是从氢、氨基、氧代和 OR 组成的组中选出的基团 4 ; 每个 R 2 是分别选自氢、氨基和 OR 4 ; 每个 R 3 是分别选自由氢、碳水化合物和碳水化合物衍生物组成的基团； "X" 是一个基团，选自由 -CH 2 -、-O- 和-NH 2 -；以及 其中化合物包括至少一个 R 4 基团是碳水化合物或其衍生物，例如选自由甘油醛、甘油糖、赤藓糖、苏糖、核糖、阿拉伯糖、木糖、莱克糖、阿拓糖、阿洛糖、古洛糖、甘露糖、葡萄糖、idose饴糖、半乳糖、塔尔糖、鼠李糖、二羟基内酯、赤藓糖醇、核酮糖、木糖、棉子糖、果糖、山梨糖、塔格糖，以及其他六糖、庚糖、辛糖、纳糖、癸糖、带支链的脱氧糖（如apiose、hamamelose）。如apiose、hamamelose、streptose、cordycepose、mycarose 和 cladinose），醛基、酮基或羟基被取代的化合物（如 N-乙酰基、乙酰基、甲基、取代 CH 2 OH）、糖醇、糖酸、苯并咪唑、碳水化合物的烯醇盐、糖精酸、糖磷酸盐；作为 IL-6 拮抗剂。